TY - JOUR KW - Clofazimine KW - Dapsone KW - Drug Evaluation KW - Drug Therapy, Combination KW - Humans KW - leprosy KW - Male KW - Rifampin KW - Sepsis KW - Thioacetazone AU - Ramu G AU - Sengupta U AU - Desikan K V AB -
Assessment of bacteraemia has been made at weekly intervals in 36 lepromatous leprosy patients who were put on different antileprosy drug under four regimens, viz., DDS alone, DDS in combination with rifampicin (DDS + RIF), clofazimine (DDS + CLF) and thiacetazone (DDS + TCT). In general, with the continuation of treatment the bacillary load in the blood decreased considerably while bacteriological index (BI) of the skin remained constant during the study. No significant difference was noted in M. leprae clearance from blood between the groups treated with DDS alone and groups treated in combination with CLF and TCT. However, DDS + RIF treatment was most efficient in clearing acid-fast bacilli (AFB) from blood as compared to those noted with other drug regimens.
BT - Leprosy in India C1 - http://www.ncbi.nlm.nih.gov/pubmed/6166790?dopt=Abstract CN - Infolep Library - available DA - 1981 Apr IS - 2 J2 - Lepr India LA - eng N2 -Assessment of bacteraemia has been made at weekly intervals in 36 lepromatous leprosy patients who were put on different antileprosy drug under four regimens, viz., DDS alone, DDS in combination with rifampicin (DDS + RIF), clofazimine (DDS + CLF) and thiacetazone (DDS + TCT). In general, with the continuation of treatment the bacillary load in the blood decreased considerably while bacteriological index (BI) of the skin remained constant during the study. No significant difference was noted in M. leprae clearance from blood between the groups treated with DDS alone and groups treated in combination with CLF and TCT. However, DDS + RIF treatment was most efficient in clearing acid-fast bacilli (AFB) from blood as compared to those noted with other drug regimens.
PY - 1981 SP - 190 EP - 6 T2 - Leprosy in India TI - Evaluation of multiple regimens in leprosy. VL - 53 SN - 0024-1024 ER -